Venture Capital Investors

Burrill & Company

Burrill & Company is a venture capital investment firm that helps tech companies seeking to achieve their full potential.

Venture Investor Overview

Venture Investor
Burrill & Company
Status
InActive
Investor Type
Venture Capital
Activity Level
95 transactions
Funds Raised
Unknown
Industry Focus
Healthcare IT

Contact Information

Contact
Steven Burrill
Title
Chief Executive Officer
Mailing Address
Buynow Science and Technology Building No.25 Renmin Road 1413-1414
Wuxi City, 214000
China
Phone
+0510-85875665
Website
www.burrillandco.com
Email Address
Not Recorded

Background Information

Overview
Burrill & Co is a diversified equity firm specializing in various Life Science sectors. It provides venture capital and merchant banking services.
Profile
Burrill & Company LinkedIn Company Profile
Social Media
Burrill & Company Company Twitter Account
Company News
Burrill & Company News
Facebook
Burrill & Company on Facebook
YouTube
Burrill & Company on YouTube
Last Transaction
4/17/2014

Transaction History

Our records indicate that Burrill & Company invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Nora Therapeutics
4/17/2014
$18,000,000
Neos Therapeutics
3/4/2014
$15,500,000
BetterDoctor
10/22/2013
$2,600,000
WaveTec Vision Systems
6/24/2013
$11,000,000
Catalyst Biosciences
3/31/2013
$5,072,000
Odyssey Thera
2/15/2013
$2,800,000
MabVax Therapeutics
11/23/2012
$5,250,000
AliveCor
6/11/2012
$10,500,000
Ceptaris Therapeutics
6/5/2012
$10,000,000
WhiteGlove Health
4/12/2012
$12,900,000
WaveTec Vision Systems
4/10/2012
$16,500,000
Chromatin
3/31/2012
$1,600,800
SCYNEXIS
3/31/2012
$222,000
Virdia
3/6/2012
$30,000,000
SCYNEXIS
12/31/2011
$5,503,200
AliveCor
8/12/2011
$3,000,000
Ceptaris Therapeutics
8/11/2011
$14,400,000
Wellpartner
6/30/2011
$25,200
Cobalt Technologies
5/2/2011
$20,000,000
Nora Therapeutics
6/30/2010
$1,932,000
Gevo
6/30/2010
$16,150,200
Ferrokin BioSciences
6/17/2010
$12,000,000
Logical Therapeutics
5/27/2010
$16,900,000
Odyssey Thera
3/17/2010
$3,500,000
Akermin
1/26/2010
$10,000,000
Neurotech Pharmaceuticals
12/31/2009
$5,700,100
Efficas
12/31/2009
$500,000
Endocyte
10/18/2009
$26,000,000
PrimeraDx
9/21/2009
$20,000,000
XDx
8/5/2009
$14,400,000
Virdia
6/1/2009
Unknown
Osprey Pharmaceuticals
5/27/2009
$3,800,000
TRF Pharma
3/31/2009
$6,000,000
Logical Therapeutics
12/31/2008
$6,000,000
Odyssey Thera
12/31/2008
$10,676,000
Catalyst Biosciences
12/3/2008
$40,400,000
Arete Therapeutics
11/19/2008
$16,700,000
Ferrokin BioSciences
11/5/2008
$8,400,000
Chromatin
11/3/2008
$12,400,000
ProteoGenix
9/30/2008
$8,000,000
Osprey Pharmaceuticals
9/3/2008
$11,000,000
BioImagene
8/20/2008
$26,000,000
Wellpartner
8/1/2008
$16,100,000
Ikano Therapeutics
6/30/2008
$9,000,000
Proventys
5/15/2008
$5,650,000
Gevo
5/13/2008
$17,000,000
NanoVasc
3/31/2008
$4,745,000
Alinea Pharmaceuticals
3/31/2008
$2,000,000
SCYNEXIS
3/24/2008
$13,500,000
PrimeraDx
1/8/2008
$21,000,000
Catalyst Biosciences
12/31/2007
$13,480,000
Logical Therapeutics
6/13/2007
$30,000,000
Phytomedics
6/12/2007
$9,000,000
Sciona
6/11/2007
$3,400,000
Arete Therapeutics
5/23/2007
$13,300,000
The Natural Dentist
4/25/2007
$13,000,000
Ikano Therapeutics
3/31/2007
$3,000,000
Aerovance
3/27/2007
$32,000,000
Endocyte
3/23/2007
$15,000,000
ProteoGenix
3/9/2007
$20,000,000
diaDexus
1/12/2007
$40,000,000
Natural Dentist
12/31/2006
$8,399,900
Neurotech Pharmaceuticals
11/16/2006
$35,000,000
Morphotek
10/12/2006
$40,000,000
Ikano Therapeutics
8/15/2006
$39,100,000
Sciona
6/30/2006
$6,500,000
Aerovance
5/4/2006
$60,000,000
Cardiokine
5/1/2006
$50,000,000
Proventys
3/31/2006
$1,000,000
diaDexus
3/31/2006
$7,500,000
Catalyst Biosciences
2/9/2006
$30,000,000
Adlyfe
1/18/2006
$3,300,000
XDx
1/5/2006
$26,500,000
Alinea Pharmaceuticals
10/20/2005
$45,000,000
PrimeraDx
7/11/2005
$11,000,000
Nucleonics
6/30/2005
$6,000,000
elbion NV
5/24/2005
$44,566,000
Wright Medical
5/18/2005
$11,800,000
Sciona
2/28/2005
$8,200,000
Arete Therapeutics
2/21/2005
$15,000,000
elbion NV
1/10/2005
$31,837,200
Alexza Pharmaceuticals
1/6/2005
$52,000,000
Endocyte
12/6/2004
$23,000,000
Catalyst Biosciences
12/4/2004
$40,000,000
Neosil
11/8/2004
$32,000,000
Wright Medical
11/4/2004
$25,700,000
Aerovance
8/23/2004
$32,000,000
Pharmasset
8/10/2004
$40,000,000
Nucleonics
6/20/2004
$49,200,000
Cardiokine
4/13/2004
$37,000,000
Morphotek
2/18/2004
$26,000,000
Phytomedics
1/20/2004
$7,500,000
Cellomics
1/9/2004
$5,300,000
ImmunGene
7/11/2003
$25,000,000
Targacept
3/19/2003
$60,000,000

 

Investor Contacts

Title
Name
Email & Social
Managing Director
Joao Baptista
  Joao Baptista LinkedIn Profile  Joao Baptista Twitter Account  Joao Baptista News  Joao Baptista on Facebook
Chief Executive Officer
Steven Burrill
  Steven Burrill LinkedIn Profile  Steven Burrill Twitter Account  Steven Burrill News  Steven Burrill on Facebook
Managing Director
Bryant Fong
  Bryant Fong LinkedIn Profile  Bryant Fong Twitter Account  Bryant Fong News  Bryant Fong on Facebook
Managing Director
Frederick Frank
  Frederick Frank LinkedIn Profile  Frederick Frank Twitter Account  Frederick Frank News  Frederick Frank on Facebook
Managing Director
Ann Hanham
  Ann Hanham LinkedIn Profile  Ann Hanham Twitter Account  Ann Hanham News  Ann Hanham on Facebook
Managing Director
Douglas Lind
  Douglas Lind LinkedIn Profile  Douglas Lind Twitter Account  Douglas Lind News  Douglas Lind on Facebook
Managing Director
Mary Tanner
  Mary Tanner LinkedIn Profile  Mary Tanner Twitter Account  Mary Tanner News  Mary Tanner on Facebook
Managing Director
James Watson
  James Watson LinkedIn Profile  James Watson Twitter Account  James Watson News  James Watson on Facebook
Managing Director
Roger Wyse
  Roger Wyse LinkedIn Profile  Roger Wyse Twitter Account  Roger Wyse News  Roger Wyse on Facebook

 

Funds

No fund closings have been recorded for this company.

 

Portfolio Companies

Burrill & Company has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
Adlyfe
Aerovance
Akermin
Alexza Pharmaceuticals
Alinea Pharmaceuticals
AliveCor
Arete Therapeutics
BetterDoctor
BioImagene
Cardiokine
Catalyst Biosciences
Cellomics
Ceptaris Therapeutics
Chromatin
Cobalt Technologies
diaDexus
Efficas
elbion NV
Endocyte
Ferrokin BioSciences
Gevo
Ikano Therapeutics
ImmunGene
Logical Therapeutics
MabVax Therapeutics
Morphotek
NanoVasc
Natural Dentist
Neos Therapeutics
Neosil
Neurotech Pharmaceuticals
Nora Therapeutics
Nucleonics
Odyssey Thera
Osprey Pharmaceuticals
Pharmasset
Phytomedics
PrimeraDx
ProteoGenix
Proventys
Sciona
SCYNEXIS
Targacept
The Natural Dentist
TRF Pharma
Virdia
WaveTec Vision Systems
Wellpartner
WhiteGlove Health
Wright Medical
XDx

 

 

 

 

Browse more venture capital investors:

Burnt Island Ventures | Burst Capital

 

Share this article

 

About Our VC & M&A Database

This VC firm profile is powered by VentureDeal.com, a market leader in private equity transaction data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.